Company intelligence / Profile preview

PAM Theragnostics

Hennigsdorf, Brandenburg, Germanypam-t.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Currently in preclinical development of the PAM enzyme as a drug candidate for Alzheimer's disease prevention. The company has developed an immunoassay for PAM quantification in human plasma and is initiating GMP production.

Therapeutic areas: CardiovascularNeurology
Modalities: Enzyme therapy (PAM enzyme)
Industry: Biotech

Drug pipeline

2 assets

PAM Therapy

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on PAM Theragnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAM Theragnostics.

Explore the full profile